STAT+: Pharmalittle: We're reading about Trump's MFN deals, 340B program controversies, and much more

Ali Nemati3 hours ago28 sec read9 views

The Trump administration's most-favored nation drug pricing deals with 16 pharmaceutical companies are set to expire after three years, impacting drug prices for cash-paying customers and Medicaid; this has introduced uncertainty in Europe regarding potential price hikes and access to medicines. For content creators, the evolving landscape of international drug pricing and its impact on healthcare systems provides a critical area for ongoing coverage and analysis.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

STAT+: Pharmalittle: We're reading about FDA and a 'smear campaign,' Cigna buying a large pharmacy, and more

The U.S. FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top official Vinay Prasad against a perceived "smear campa...The U.S. FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top official Vinay Prasad against a perceived "smear campaign," while Cigna acquired CarepathRx to strengthen its control over pharmaceutical distribution in ...

Ali Nemati

Biotech & Pharma4 days ago27 sec read

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top FDA official Vinay Prasad against criticism, emphasizing the ag...FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top FDA official Vinay Prasad against criticism, emphasizing the agency's commitment to rigorous standards despite pressure for approvals. This stance underscores the ...

Ali Nemati

Biotech & Pharma4 days ago33 sec read

STAT+: Pharmalittle: We're reading about a puzzling FDA rejection, a Lilly weight loss pill, and more

An experimental therapy for a rare blood cancer, Ebvallo, was unexpectedly rejected by the FDA despite internal recommendations for approval, indicati...An experimental therapy for a rare blood cancer, Ebvallo, was unexpectedly rejected by the FDA despite internal recommendations for approval, indicating a potentially higher approval threshold for rare disease treatments. Direct-to-consumer websites ...

Ali Nemati

Health & Medicine4 days ago27 sec read

STAT+: Brain implants: What's standing in the way of pivotal trials, FDA approval

Mike Willis, affected by a neurodegenerative disorder that has robbed him of speech, highlights the urgent need for brain implant technology; however,...Mike Willis, affected by a neurodegenerative disorder that has robbed him of speech, highlights the urgent need for brain implant technology; however, regulatory hurdles and clinical trial challenges are impeding progress towards FDA approval. For co...

Ali Nemati

Health & Medicine4 days ago21 sec read

STAT+: A rare disease drug was approvable, then it wasn't. Inside a surprise rejection by the FDA

The FDA unexpectedly rejected a rare blood cancer drug developed by Atara Biotherapeutics and Pierre Fabre Pharmaceuticals after internal reviewers ha...The FDA unexpectedly rejected a rare blood cancer drug developed by Atara Biotherapeutics and Pierre Fabre Pharmaceuticals after internal reviewers had initially recommended approval; this reversal highlights potential shifts under new leadership at ...

Ali Nemati

STAT+: Pharmalittle: We're reading about Trump's MFN deals, 340B program controversies, and much more

Related Articles

STAT+: Pharmalittle: We're reading about FDA and a 'smear campaign,' Cigna buying a large pharmacy, and more

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

STAT+: Pharmalittle: We're reading about a puzzling FDA rejection, a Lilly weight loss pill, and more

STAT+: Brain implants: What's standing in the way of pivotal trials, FDA approval

STAT+: A rare disease drug was approvable, then it wasn't. Inside a surprise rejection by the FDA